SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* MONTANOVA CAPITAL, LLC (Last) (First) (Middle) 11 E 26TH STREET 16TH FLOOR (Street) NEW YORK NY 10010 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Veradermics, Inc [ MANE ] Foreign Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 08/19/2026
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock, par value $0.00001 per share	08/19/2026		S		690,601(2)	D	$107.25	2,957,937	I(1)	See footnotes(1)(2)
Common stock, par value $0.00001 per share	08/19/2026		S		59,399(3)	D	$107.25	461,033	I(1)	See footnotes(1)(3)
Common stock, par value $0.00001 per share	08/20/2026		X		149,000(4)	A	(6)	3,106,937	I(1)	See footnotes(1)(4)
Common stock, par value $0.00001 per share	08/20/2026		X		151,000(5)	A	(6)	612,033	I(1)	See footnotes(1)(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Pre-Funded Warrants	(6)	08/20/2026		X			149,000(4)	(7)(8)	(7)	Common Stock	149,000(7)	$0	0	I(1)	See footnotes(1)(4)
Pre-Funded Warrants	(6)	08/20/2026		X			151,000(5)	(7)(8)	(7)	Common Stock	151,000(7)	$0	0	I(1)	See footnotes(1)(5)

1. Name and Address of Reporting Person* MONTANOVA CAPITAL, LLC (Last) (First) (Middle) 11 E 26TH STREET 16TH FLOOR (Street) NEW YORK NY 10010 (City) (State) (Zip)

1. Name and Address of Reporting Person* Cowen Aaron (Last) (First) (Middle) C/O MONTANOVA CAPITAL, LLC 11 E 26TH, 16TH FLOOR (Street) NEW YORK NY 10010 (City) (State) (Zip)

1. Name and Address of Reporting Person* Averill Master Fund, Ltd. (Last) (First) (Middle) C/O MONTANOVA CAPITAL, LLC 11 E 26TH, 16TH FLOOR (Street) NEW YORK NY 10010 (City) (State) (Zip)

1. Name and Address of Reporting Person* Averill Madison Master Fund, Ltd. (Last) (First) (Middle) C/O MONTANOVA CAPITAL, LLC 11 E 26TH, 16TH FLOOR (Street) NEW YORK NY 10010 (City) (State) (Zip)

Explanation of Responses:

1. Notes are included on Exhibit 99.1.

2. Notes are included on Exhibit 99.1.

3. Notes are included on Exhibit 99.1.

4. Notes are included on Exhibit 99.1.

5. Notes are included on Exhibit 99.1.

6. Notes are included on Exhibit 99.1.

7. Notes are included on Exhibit 99.1.

8. Notes are included on Exhibit 99.1.

Remarks:

Exhibit List: Exhibit 99.1 - Explanation of Responses Exhibit 99.2 - Joint Filer Information Exhibit 99.3 - Joint Filers' Signature

	Montanova Capital, LLC; By: /s/ Andrew Nathanson, General Counsel & Chief Compliance Officer	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

(1)	This Form 4 is filed on behalf of Averill Master Fund, Ltd., a Cayman Islands exempted company (“Averill Master Fund”), Averill Madison Master Fund, Ltd., a Cayman Islands exempted company (“Averill Madison Master Fund” and, together with the Averill Master Fund, the “Funds”), Montanova Capital, LLC, a Delaware limited liability company (“Montanova Capital”), and Aaron Cowen (“Mr. Cowen”) (collectively, the “Reporting Persons”). Montanova Capital is the investment manager of the Funds. Mr. Cowen may be deemed to control Montanova Capital and therefore may be deemed to beneficially own shares of Common Stock (as defined below) held by the Funds. Mr. Cowen disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any indirect pecuniary interest therein. The securities reported herein are directly held by either Averill Master Fund or Averill Madison Master Fund as noted herein. Each of the Funds and Montanova Capital may be deemed a director by deputization by virtue of David Friedman, M.D., a Managing Director and Senior Analyst at Montanova Capital, serving on the board of directors of the Issuer (as defined below). For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any and all shares by the Reporting Persons as a result of or in connection with the transactions reported in this Form 4.
(2)	These shares of common stock, par value $0.00001 per share (the “Common Stock”), of Veradermics, Incorporated (the “Issuer”) were sold by Averill Master Fund in an open market transaction.
(3)	These shares of Common Stock of the Issuer were sold by Averill Madison Master Fund in an open market transaction.
(4)	Represents the exercise of pre-funded warrants to purchase Common Stock of the Issuer at an exercise price of $0.00001 per share, subject to adjustment pursuant their terms (the “Pre-Funded Warrants”) directly held by Averill Master Fund acquired as part of the Issuer’s private placement in May 2026.
(5)	Represents the exercise of Pre-Funded Warrants directly held by Averill Madison Master Fund acquired as part of the Issuer’s private placement in May 2026 at a price of $99.9999 per Pre-Funded Warrant.
(6)	The exercise price of each Pre-Funded Warrant was $0.00001 per share, subject to adjustment pursuant to the terms of the Pre-Funded Warrants.
(7)	The Pre-Funded Warrants reflected herein had no expiration date and were exercisable at any time after their applicable original issuance to the extent that immediately prior to or following such exercise, the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, collectively beneficially owned or would have beneficially owned as determined in accordance with Section 13(d) of the Exchange Act and the rules promulgated thereunder, no more than 9.99% of the Common Stock that would have been issued and outstanding following such exercise (the “Beneficial Ownership Limitation”). The number of shares underlying such Pre-Funded Warrants is reported herein without regard to any limitations on exercise contained therein.
(8)	By written notice to the Issuer, Averill Master Fund and Averill Madison Master Fund were permitted to increase or decrease the Beneficial Ownership Limitation applicable to that Fund, together with its affiliates and any members of a Section 13(d) group with such Fund, to any other percentage not in excess of 19.99%; provided that any such increase would not have been effective until the 61st day after such notice was delivered to the Issuer and would not have negatively affected any partial exercise effected prior to such change.

1. Name:	Aaron Cowen
Address:	c/o Montanova Capital, LLC
	11 E 26th Street, 16th Floor
	New York, NY 10010
2. Name:	Averill Master Fund, Ltd.
Address:	c/o Montanova Capital, LLC
	11 E 26th Street, 16th Floor
	New York, NY 10010
3. Name:	Averill Madison Master Fund, Ltd.
Address:	c/o Montanova Capital, LLC
	11 E 26th Street, 16th Floor
	New York, NY 10010

By: /s/ Andrew Nathanson		Date: August 21, 2026
	Name: Andrew Nathanson
	Title: Authorized Signatory
AVERILL MADISON MASTER FUND, LTD.
By: /s/ Andrew Nathanson		Date: August 21, 2026
	Name: Andrew Nathanson
	Title: Authorized Signatory
By: /s/ Aaron Cowen		Date: August 21, 2026
	Name: Aaron Cowen